Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders After Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Feb 7

PMID 32024048

Citations 17

Authors

Ayumi Fujimoto

Ritsuro Suzuki

Affiliations

Soon will be listed here.

Abstract

Epstein-Barr virus (EBV) is a ubiquitous virus belonging to the human -herpes virus subfamily. After primary infection, EBV maintains a life-long latent infection. A major concern is that EBV can cause a diverse range of neoplasms and autoimmune diseases. In addition, patients undergoing hematopoietic stem cell transplantation or solid organ transplantation can experience post-transplant lymphoproliferative disorders (PTLDs) due to dysfunction or suppression of host's immune system, or uncontrolled proliferation of EBV-infected cells. In recent years, the number of EBV-associated PTLD cases has increased. This review focuses on the current understandings of EBV-associated PTLD pathogenesis, as well as the risk factors and clinical outcomes for patients after allogeneic stem cell transplantation.

Citing Articles

Performance evaluation of the high-throughput quantitative Alinity m Epstein-Barr virus assay.

Goldstein D, Sasaki M, Narlieva M, Nhan N, Liu T, Kegl A Microbiol Spectr. 2024; 13(1):e0150724.

PMID: 39545735 PMC: 11705799. DOI: 10.1128/spectrum.01507-24.

Epstein-Barr virus positive post-transplant lymphoproliferative disorder with significantly decreased T-cell chimerism early after transplantation: A case report.

Guo Q, Liu H, Li L, Jin D, Shi J, Lai X World J Radiol. 2024; 16(10):600-607.

PMID: 39494132 PMC: 11525832. DOI: 10.4329/wjr.v16.i10.600.

Metachronous spinal cord involvement B cell and subcutaneous tissue involvement NK/T cell lymphoid proliferations and lymphomas arising in post-transplantation mimicking general NK/T cell lymphoma: a case report and review of the literature.

Zhu Y, He L, Zou H, Yao S, Hu J, Guo J Front Immunol. 2024; 15:1467506.

PMID: 39469712 PMC: 11513307. DOI: 10.3389/fimmu.2024.1467506.

Elucidating the nexus between onco-immunology and kidney transplantation: An insight from precision medicine perspective.

Purnomo A, Nurkolis F, Syahputra R, Moon S, Lee D, Taslim N Heliyon. 2024; 10(13):e33751.

PMID: 39040404 PMC: 11261886. DOI: 10.1016/j.heliyon.2024.e33751.

Posttransplant Lymphoproliferative Disorder in a Patient With Alpha-1 Antitrypsin Deficiency: A Case Report.

Joly L, Virgilio R, Yother C Cureus. 2024; 16(6):e62107.

PMID: 38993443 PMC: 11238152. DOI: 10.7759/cureus.62107.

References

Evens A, David K, Helenowski I, Nelson B, Kaufman D, Kircher S . Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010; 28(6):1038-46. PMC: 2834429. DOI: 10.1200/JCO.2009.25.4961. View

Panagiotidis E, Quigley A, Pencharz D, Ardeshna K, Syed R, Sajjan R . (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder. Leuk Lymphoma. 2013; 55(3):515-9. DOI: 10.3109/10428194.2013.813501. View

Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C . Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Transpl Infect Dis. 2019; 21(5):e13145. PMC: 7239317. DOI: 10.1111/tid.13145. View

Green M, Rodig S, Juszczynski P, Ouyang J, Sinha P, ODonnell E . Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012; 18(6):1611-8. PMC: 3321508. DOI: 10.1158/1078-0432.CCR-11-1942. View

Granato M, Romeo M, Tiano M, Santarelli R, Gonnella R, Gilardini Montani M . Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy. Sci Rep. 2017; 7(1):13052. PMC: 5638868. DOI: 10.1038/s41598-017-13533-7. View

Terrin L, Dolcetti R, Corradini I, Indraccolo S, Dal Col J, Bertorelle R . hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis. Int J Cancer. 2007; 121(3):576-87. DOI: 10.1002/ijc.22661. View

Koon H, Ippolito G, Banham A, Tucker P . FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets. 2007; 11(7):955-65. PMC: 4282158. DOI: 10.1517/14728222.11.7.955. View

Delapierre B, Reman O, Dina J, Breuil C, Bellal M, Johnson-Ansah H . Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation. Curr Res Transl Med. 2019; 67(4):145-148. DOI: 10.1016/j.retram.2019.03.001. View

Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo M, Calore E . The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2005; 128(2):224-33. DOI: 10.1111/j.1365-2141.2004.05287.x. View

10.

Heslop H, Slobod K, Pule M, Hale G, Rousseau A, Smith C . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2009; 115(5):925-35. PMC: 2817637. DOI: 10.1182/blood-2009-08-239186. View

11.

Leonard S, Wei W, Anderton J, Vockerodt M, Rowe M, Murray P . Epigenetic and transcriptional changes which follow Epstein-Barr virus infection of germinal center B cells and their relevance to the pathogenesis of Hodgkin's lymphoma. J Virol. 2011; 85(18):9568-77. PMC: 3165764. DOI: 10.1128/JVI.00468-11. View

12.

Kinch A, Cavelier L, Bengtsson M, Baecklund E, Enblad G, Backlin C . Donor or recipient origin of posttransplant lymphoproliferative disorders following solid organ transplantation. Am J Transplant. 2014; 14(12):2838-45. DOI: 10.1111/ajt.12990. View

13.

Szabolcs P, Cairo M . Unrelated umbilical cord blood transplantation and immune reconstitution. Semin Hematol. 2010; 47(1):22-36. PMC: 3684393. DOI: 10.1053/j.seminhematol.2009.10.009. View

14.

Styczynski J, van der Velden W, Fox C, Engelhard D, de la Camara R, Cordonnier C . Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016; 101(7):803-11. PMC: 5004459. DOI: 10.3324/haematol.2016.144428. View

15.

Ferrara J, Cooke K, Teshima T . The pathophysiology of acute graft-versus-host disease. Int J Hematol. 2003; 78(3):181-7. DOI: 10.1007/BF02983793. View

16.

Leblond V, Davi F, Charlotte F, Dorent R, Bitker M, Sutton L . Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?. J Clin Oncol. 1998; 16(6):2052-9. DOI: 10.1200/JCO.1998.16.6.2052. View

17.

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

18.

Dierickx D, Habermann T . Post-Transplantation Lymphoproliferative Disorders in Adults. N Engl J Med. 2018; 378(6):549-562. DOI: 10.1056/NEJMra1702693. View

19.

Gustafsson A, Levitsky V, Zou J, Frisan T, Dalianis T, Ljungman P . Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000; 95(3):807-14. View

20.

Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V . Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005; 106(9):3183-90. PMC: 1895326. DOI: 10.1182/blood-2005-04-1399. View